Virpax Pharmaceuticals, known as VRPX in the U.S. stock market, received a communication from the United States Securities and Exchange Commission (SEC) on April 23, 2024. The SEC informed the company that it will not review the Registration Statement on Form S-1 that Virpax Pharmaceuticals filed on April 18, 2024. The SEC's letter, addressed to Gerald Bruce, the CEO of Virpax Pharmaceuticals, also reminded the company of its responsibility for the accuracy and adequacy of its disclosures. The SEC pointed out Rules 460 and 461, which pertain to requests for acceleration of the registration process. Daniel Crawford from the Division of Corporation Finance Office of Life Sciences is the contact person for any further inquiries from Virpax Pharmaceuticals.

Virpax Pharmaceuticals, known as VRPX in the U.S. stock market, received a communication from the United States Securities and Exchange Commission (SEC) on April 23, 2024. The SEC informed the company that it will not review the Registration Statement on Form S-1 that Virpax Pharmaceuticals filed on April 18, 2024. The SEC's letter, addressed to Gerald Bruce, the CEO of Virpax Pharmaceuticals, also reminded the company of its responsibility for the accuracy and adequacy of its disclosures. The SEC pointed out Rules 460 and 461, which pertain to requests for acceleration of the registration process. Daniel Crawford from the Division of Corporation Finance Office of Life Sciences is the contact person for any further inquiries from Virpax Pharmaceuticals.